Back to Search Start Over

Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-CoV-2 Infection and COVID-19-Associated Immunothrombosis

Authors :
José T. Ortiz-Pérez
Albert Morales
Montserrat Marí
Pablo García de Frutos
Anna Tutusaus
Gerry A. F. Nicolaes
Ministerio de Ciencia, Innovación y Universidades (España)
Agencia Estatal de Investigación (España)
Instituto de Salud Carlos III
European Commission
Generalitat de Catalunya
Tutusaus, Anna [0000-0002-1133-321X]
Marí, Montserrat [0000-0002-6116-3247]
Ortiz-Pérez, José T. [0000-0001-8043-6055]
Morales, Albert [0000-0001-8702-2269]
García de Frutos, Pablo [0000-0003-1547-1190]
Tutusaus, Anna
Marí, Montserrat
Ortiz-Pérez, José T.
Morales, Albert
García de Frutos, Pablo
Source :
Digital.CSIC. Repositorio Institucional del CSIC, instname, Cells, Vol 9, Iss 2186, p 2186 (2020), Cells
Publication Year :
2020

Abstract

The vitamin K-dependent factors protein S (PROS1) and growth-arrest-specific gene 6 (GAS6) and their tyrosine kinase receptors TYRO3, AXL, and MERTK, the TAM subfamily of receptor tyrosine kinases (RTK), are key regulators of inflammation and vascular response to damage. TAM signaling, which has largely studied in the immune system and in cancer, has been involved in coagulation-related pathologies. Because of these established biological functions, the GAS6-PROS1/TAM system is postulated to play an important role in SARS-CoV-2 infection and progression complications. The participation of the TAM system in vascular function and pathology has been previously reported. However, in the context of COVID-19, the role of TAMs could provide new clues in virus-host interplay with important consequences in the way that we understand this pathology. From the viral mimicry used by SARS-CoV-2 to infect cells, to the immunothrombosis that is associated with respiratory failure in COVID-19 patients, TAM signaling seems to be involved at different stages of the disease. TAM targeting is becoming an interesting biomedical strategy, which is useful for COVID-19 treatment now, but also for other viral and inflammatory diseases in the future.<br />This research was funded by MINISTERIO DE CIENCIA E INNOVACIÓN (Project# RTI2018-095672-B-I00 to A.M. and P.G.F), and by INSTITUTO DE SALUD CARLOS III (Project# PI19/01410 to M.M. and project# PI15/00531 to J.T.O.P) and co-funded by EUROPEAN UNION (ERDF “A way to make Europe”). AGAUR (2017_SGR_177) and CERCA Programme/Generalitat de Catalunya

Details

Language :
English
ISSN :
20734409
Volume :
9
Issue :
10
Database :
OpenAIRE
Journal :
Cells
Accession number :
edsair.doi.dedup.....ce3181d1ac3271abd2b360d1f5b29f0e
Full Text :
https://doi.org/10.3390/cells9102186